A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension

This study has been terminated.
(Study terminated due to corporate decision.)
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01781962
First received: January 30, 2013
Last updated: November 6, 2013
Last verified: November 2013
  Purpose

This study will assess angle width in Chinese patients with Open-angle Glaucoma and/or Ocular Hypertension.


Condition Intervention
Open-angle Glaucoma
Ocular Hypertension
Other: No Treatment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:


Further study details as provided by Allergan:

Primary Outcome Measures:
  • Anterior Angle Width as Measured by Anterior Segment Optical Coherence Tomography [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anterior Angle Width as Measured by Gonioscopic Lens with Shaffer Grading [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
  • Anterior Angle Width as Measured by Gonioscopic Lens with Step Grading [ Time Frame: Day 1 ] [ Designated as safety issue: No ]

Enrollment: 205
Study Start Date: January 2013
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
OAG and/or OHT patients
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Other: No Treatment
No Treatment was given in this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Chinese patients with Open-angle Glaucoma and/or Ocular Hypertension

Criteria

Inclusion Criteria:

  • Of Chinese descent
  • Open-angle Glaucoma or Ocular Hypertension in each eye

Exclusion Criteria:

  • History of a narrow-angle or angle closure glaucoma
  • Angle abnormalities in either eye
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01781962

Locations
China
Beijing, China
Sponsors and Collaborators
Allergan
Investigators
Study Director: Medical Director Allergan
  More Information

No publications provided

Responsible Party: Allergan
ClinicalTrials.gov Identifier: NCT01781962     History of Changes
Other Study ID Numbers: 192024-077
Study First Received: January 30, 2013
Last Updated: November 6, 2013
Health Authority: China: Ethics Committee

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Hypertension
Ocular Hypertension
Eye Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 26, 2014